Clearside Biomedical predicts its uveitis drug will be rejected, after FDA requests more data

In its second-quarter update earlier this month, eye drug developer Clearside Biomedical indicated it was looking to out-license its lead drug, Xipere, which is currently under FDA review. But those plans may be put on hold after the company on Thursday disclosed the FDA has asked for more data on the drug’s marketing application.